Clinical Trial

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

Study acronym: NUTMEG
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma. Who is it for? You may be eligible to join this study if you are aged 65 years or above, with newly diagnosed histologically confirmed GBM (WHO grade IV glioma including gliosarcoma) following surgery. The study aims to evaluate whether the combination of adjuvant nivolumab with temozolomide improves overall survival outcomes for this patient population. The outcome of the study will help determine the most effective treatment for patients with glioblastoma in the future.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-12-09; most recent amendment 2024-12-05.
Status change: Recruiting → Active, Not Recruiting 2021-06-28
Trial Details
NCT Number NCT04195139
Lead Sponsor University of Sydney
Collaborators: Cooperative Trials Group for Neuro-Oncology
Conditions Glioblastoma Multiforme
Enrollment 103 participants
Start Date 2018-02-22
Primary Completion 2024-06-28 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-11